Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells

Luciano Castiello, Paola Sestili, Giovanna Schiavoni, Rosanna Dattilo, Domenica M. Monque, Fiorella Ciaffoni, Manuela Iezzi, Alessia Lamolinara, Antonella Sistigu, Federica Moschella, Anna Maria Pacca, Daniele Macchia, Maria Ferrantini, Ann Zeuner, Mauro Biffoni, Enrico Proietti, Filippo Belardelli, Eleonora Aricò

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spontaneous, oncogene-driven carcinogenesis, we characterized tumors arising in HER2/neu transgenic (neuT) mice carrying a nonfunctional mutation in the IFNI receptor (IFNAR1). Such mice are unresponsive to this family of cytokines. Compared with parental neumice (neuT mice), IFNAR1/ neumice (IFNAR-neuT mice) showed earlier onset and increased tumor multiplicity with marked vascularization. IFNAR-neuT tumors exhibited deregulation of genes having adverse prognostic value in breast cancer patients, including the breast cancer stem cell (BCSC) marker aldehyde dehydrogenase-1A1 (ALDH1A1).An increased number of BCSCs were observed in IFNAR-neuT tumors, as assessed by ALDH1A1 enzymatic activity, clonogenic assay, and tumorigenic capacity. In vitro exposure of neuTmmospheres and cell lines to antibodies to IFN-I resulted in increased frequency of ALDHlls, suggesting that IFN-I controls stemness in tumor cells.Altogether, these results reveal a role of IFN-I in neuT-driven spontaneous carcinogenesis through intrinsic control of BCSCs. Cancer Immunol Res; 6(6); 658-70.

Original languageEnglish
Pages (from-to)658-670
Number of pages13
JournalCancer immunology research
Volume6
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Neoplasms
Transgenic Mice
Aldehyde Dehydrogenase
Carcinogenesis
Cytokines
Interferon Type I
Oncogenes
Antiviral Agents
Cell Line
Mutation
Antibodies
Growth

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Castiello, L., Sestili, P., Schiavoni, G., Dattilo, R., Monque, D. M., Ciaffoni, F., ... Aricò, E. (2018). Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells. Cancer immunology research, 6(6), 658-670. https://doi.org/10.1158/2326-6066.CIR-17-0675

Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells. / Castiello, Luciano; Sestili, Paola; Schiavoni, Giovanna; Dattilo, Rosanna; Monque, Domenica M.; Ciaffoni, Fiorella; Iezzi, Manuela; Lamolinara, Alessia; Sistigu, Antonella; Moschella, Federica; Pacca, Anna Maria; Macchia, Daniele; Ferrantini, Maria; Zeuner, Ann; Biffoni, Mauro; Proietti, Enrico; Belardelli, Filippo; Aricò, Eleonora.

In: Cancer immunology research, Vol. 6, No. 6, 01.06.2018, p. 658-670.

Research output: Contribution to journalArticle

Castiello, L, Sestili, P, Schiavoni, G, Dattilo, R, Monque, DM, Ciaffoni, F, Iezzi, M, Lamolinara, A, Sistigu, A, Moschella, F, Pacca, AM, Macchia, D, Ferrantini, M, Zeuner, A, Biffoni, M, Proietti, E, Belardelli, F & Aricò, E 2018, 'Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells', Cancer immunology research, vol. 6, no. 6, pp. 658-670. https://doi.org/10.1158/2326-6066.CIR-17-0675
Castiello, Luciano ; Sestili, Paola ; Schiavoni, Giovanna ; Dattilo, Rosanna ; Monque, Domenica M. ; Ciaffoni, Fiorella ; Iezzi, Manuela ; Lamolinara, Alessia ; Sistigu, Antonella ; Moschella, Federica ; Pacca, Anna Maria ; Macchia, Daniele ; Ferrantini, Maria ; Zeuner, Ann ; Biffoni, Mauro ; Proietti, Enrico ; Belardelli, Filippo ; Aricò, Eleonora. / Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells. In: Cancer immunology research. 2018 ; Vol. 6, No. 6. pp. 658-670.
@article{a2024139575044ba8a0280d80f3430f3,
title = "Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells",
abstract = "Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spontaneous, oncogene-driven carcinogenesis, we characterized tumors arising in HER2/neu transgenic (neuT) mice carrying a nonfunctional mutation in the IFNI receptor (IFNAR1). Such mice are unresponsive to this family of cytokines. Compared with parental neumice (neuT mice), IFNAR1/ neumice (IFNAR-neuT mice) showed earlier onset and increased tumor multiplicity with marked vascularization. IFNAR-neuT tumors exhibited deregulation of genes having adverse prognostic value in breast cancer patients, including the breast cancer stem cell (BCSC) marker aldehyde dehydrogenase-1A1 (ALDH1A1).An increased number of BCSCs were observed in IFNAR-neuT tumors, as assessed by ALDH1A1 enzymatic activity, clonogenic assay, and tumorigenic capacity. In vitro exposure of neuTmmospheres and cell lines to antibodies to IFN-I resulted in increased frequency of ALDHlls, suggesting that IFN-I controls stemness in tumor cells.Altogether, these results reveal a role of IFN-I in neuT-driven spontaneous carcinogenesis through intrinsic control of BCSCs. Cancer Immunol Res; 6(6); 658-70.",
author = "Luciano Castiello and Paola Sestili and Giovanna Schiavoni and Rosanna Dattilo and Monque, {Domenica M.} and Fiorella Ciaffoni and Manuela Iezzi and Alessia Lamolinara and Antonella Sistigu and Federica Moschella and Pacca, {Anna Maria} and Daniele Macchia and Maria Ferrantini and Ann Zeuner and Mauro Biffoni and Enrico Proietti and Filippo Belardelli and Eleonora Aric{\`o}",
year = "2018",
month = "6",
day = "1",
doi = "10.1158/2326-6066.CIR-17-0675",
language = "English",
volume = "6",
pages = "658--670",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells

AU - Castiello, Luciano

AU - Sestili, Paola

AU - Schiavoni, Giovanna

AU - Dattilo, Rosanna

AU - Monque, Domenica M.

AU - Ciaffoni, Fiorella

AU - Iezzi, Manuela

AU - Lamolinara, Alessia

AU - Sistigu, Antonella

AU - Moschella, Federica

AU - Pacca, Anna Maria

AU - Macchia, Daniele

AU - Ferrantini, Maria

AU - Zeuner, Ann

AU - Biffoni, Mauro

AU - Proietti, Enrico

AU - Belardelli, Filippo

AU - Aricò, Eleonora

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spontaneous, oncogene-driven carcinogenesis, we characterized tumors arising in HER2/neu transgenic (neuT) mice carrying a nonfunctional mutation in the IFNI receptor (IFNAR1). Such mice are unresponsive to this family of cytokines. Compared with parental neumice (neuT mice), IFNAR1/ neumice (IFNAR-neuT mice) showed earlier onset and increased tumor multiplicity with marked vascularization. IFNAR-neuT tumors exhibited deregulation of genes having adverse prognostic value in breast cancer patients, including the breast cancer stem cell (BCSC) marker aldehyde dehydrogenase-1A1 (ALDH1A1).An increased number of BCSCs were observed in IFNAR-neuT tumors, as assessed by ALDH1A1 enzymatic activity, clonogenic assay, and tumorigenic capacity. In vitro exposure of neuTmmospheres and cell lines to antibodies to IFN-I resulted in increased frequency of ALDHlls, suggesting that IFN-I controls stemness in tumor cells.Altogether, these results reveal a role of IFN-I in neuT-driven spontaneous carcinogenesis through intrinsic control of BCSCs. Cancer Immunol Res; 6(6); 658-70.

AB - Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spontaneous, oncogene-driven carcinogenesis, we characterized tumors arising in HER2/neu transgenic (neuT) mice carrying a nonfunctional mutation in the IFNI receptor (IFNAR1). Such mice are unresponsive to this family of cytokines. Compared with parental neumice (neuT mice), IFNAR1/ neumice (IFNAR-neuT mice) showed earlier onset and increased tumor multiplicity with marked vascularization. IFNAR-neuT tumors exhibited deregulation of genes having adverse prognostic value in breast cancer patients, including the breast cancer stem cell (BCSC) marker aldehyde dehydrogenase-1A1 (ALDH1A1).An increased number of BCSCs were observed in IFNAR-neuT tumors, as assessed by ALDH1A1 enzymatic activity, clonogenic assay, and tumorigenic capacity. In vitro exposure of neuTmmospheres and cell lines to antibodies to IFN-I resulted in increased frequency of ALDHlls, suggesting that IFN-I controls stemness in tumor cells.Altogether, these results reveal a role of IFN-I in neuT-driven spontaneous carcinogenesis through intrinsic control of BCSCs. Cancer Immunol Res; 6(6); 658-70.

UR - http://www.scopus.com/inward/record.url?scp=85048293803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048293803&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-17-0675

DO - 10.1158/2326-6066.CIR-17-0675

M3 - Article

AN - SCOPUS:85048293803

VL - 6

SP - 658

EP - 670

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 6

ER -